DB Securities says Aptabio's APX115 clinical results in acute kidney injury heighten expectations for technology export
Predicted impact: Low
Phase 2 trial success already reported in last 14 days; export hopes remain vague.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.